Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101

被引:43
作者
He, Chao-Bin [1 ]
Lin, Xiao-Jun [1 ]
机构
[1] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Hepatobiliary Oncol,Canc Ctr, Guangzhou, Guangdong, Peoples R China
来源
PLOS ONE | 2017年 / 12卷 / 03期
关键词
TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; P53; GENE-THERAPY; CANCER; REPLICATION; CELLS; CYCLOOXYGENASE-2; COMBINATION; EFFICACY; IMPROVES; ONYX-015;
D O I
10.1371/journal.pone.0174769
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background The systemic inflammatory response plays an important role in cancer development and progression. An original inflammation-based staging system for predicting survival in patients undergoing transarterial chemoembolization (TACE) combined with recombinant human type-5 adenovirus H101 is not available. This study aimed to validate the prognostic value of inflammation scores for patients with hepatocellular carcinoma (HCC) who were treated with TACE combined with H101. Methods The data from 216 patients with HCC who underwent TACE combined with H101 from January 2007 to July 2015 were retrospectively collected, and the association of the inflammation scores with overall survival (OS) was analyzed. Univariate and multivariate analyses were performed to identify variables associated with OS. The prognostic value of the inflammation scores, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), neutrophil/ platelet-to-lymphocyte ratio (NLR-PLR), modified Glasgow Prognostic Score (mGPS), prognostic nutritional index (PNI), prognostic index (PI), tumor-node-metastasis (TNM), Barcelona Clinic Liver Cancer (BCLC) and Cancer of the Liver Italian Program (CLIP) staging systems were analyzed and compared using the areas under the receiver operating characteristic curves (AUROCs). Results The estimated 1-, 2-, and 3-year OS rates were 61.3%, 44.2%, and 40.5% for the entire study cohort, respectively; the median OS was 17 months. According to the multivariate Cox proportional hazards model, the pretreatment NLR, tumor diameter and pretreatment alpha-fetoprotein (AFP) levels were independent predictors of OS. The CLIP score had superior discriminative abilities compared with other staging systems, and the NLR-PLR score consistently displayed a higher AUROC value than the other inflammation-based prognostic scores. The combination of the NLR-PLR and CLIP scores exhibited a superior prognostic ability for OS compared to the NLR-PLR or CLIP scores alone. Conclusions The NLR-PLR score is a more powerful predictive system than the other inflammation based scores for patients with HCC who were treated with TACE and H101. The predictive ability may be improved by utilizing a combination of the NLR-PLR and CLIP scores.
引用
收藏
页数:16
相关论文
共 56 条
  • [1] Prediction of long-term survival by using the Glasgow Prognostic Score in patients with hepatocellular carcinoma after liver transplantation
    Abe, Tomoyuki
    Tashiro, Hirotaka
    Hattori, Minoru
    Kuroda, Shintaro
    Tahara, Hiroyuki
    Ohira, Masahiro
    Kobayashi, Tsuyoshi
    Ide, Kentaro
    Ishiyama, Kohei
    Ohdan, Hideki
    [J]. HEPATOLOGY RESEARCH, 2016, 46 (07) : 622 - 633
  • [2] [Anonymous], ONCOTARGET
  • [3] [Anonymous], ONCOTARGET
  • [4] Inflammation and cancer: back to Virchow?
    Balkwill, F
    Mantovani, A
    [J]. LANCET, 2001, 357 (9255) : 539 - 545
  • [5] THE MOLECULAR-GENETICS OF CANCER
    BISHOP, JM
    [J]. SCIENCE, 1987, 235 (4786) : 305 - 311
  • [6] Chemoembolization for hepatocellular carcinoma
    Bruix, J
    Sala, M
    Llovet, JM
    [J]. GASTROENTEROLOGY, 2004, 127 (05) : S179 - S188
  • [7] Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference
    Bruix, J
    Sherman, M
    Llovet, JM
    Beaugrand, M
    Lencioni, R
    Burroughs, AK
    Christensen, E
    Pagliaro, L
    Colombo, M
    Rodés, J
    [J]. JOURNAL OF HEPATOLOGY, 2001, 35 (03) : 421 - 430
  • [8] Management of Hepatocellular Carcinoma: An Update
    Bruix, Jordi
    Sherman, Morris
    [J]. HEPATOLOGY, 2011, 53 (03) : 1020 - 1022
  • [9] Prospective validation of the Barcelona Clinic Liver Cancer staging system
    Cillo, U
    Vitale, A
    Grigoletto, F
    Farinati, F
    Brolese, A
    Zanus, G
    Neri, D
    Boccagni, P
    Srsen, N
    D'Amico, F
    Ciarleglio, FA
    Bridda, A
    D'Amico, DF
    [J]. JOURNAL OF HEPATOLOGY, 2006, 44 (04) : 723 - 731
  • [10] Inflammation and cancer
    Coussens, LM
    Werb, Z
    [J]. NATURE, 2002, 420 (6917) : 860 - 867